Pioneering a New Era of Hepatitis E Prevention
Hecolin® is the world's only vaccine for the prevention of Hepatitis E disease. It is also the world's first viral vaccine developed using an Escherichia coli expression system, completely reversing the international academic community's perception that “prokaryotic systems cannot be used for the development of viral vaccines.”
Core Advantages
Globally Unique
The world's only approved vaccine for the prevention of Hepatitis E disease.
Breakthrough and Innovation
It has changed the traditional perception of the prokaryotic expression system in the international medical community.
Widely Validated
Clinical trials involving more than 110,000 people have proven its safety and effectiveness.
International Expansion
The first Chinese vaccine product to conduct clinical trials in the United States.
Development Process
Fourteen years of dedicated research and development have forged a milestone in Hepatitis E prevention.
1998
The research and development project of the Hecolin® Hepatitis E Vaccine was launched, and the method for developing the Hepatitis E Vaccine began to be explored.
2007
Pre-clinical research was completed, and the research and development route of the Hepatitis E Vaccine based on the Escherichia coli expression system was established.
2009
It was selected for the Exhibition of Scientific and Technological Achievements on the 60th Anniversary of the Founding of the People's Republic of China.
2010
It won the “Second Prize of the National Technological Invention Award.”
2011
Hecolin® was approved for marketing by the National Medical Products Administration, becoming the world's first and only vaccine for the prevention of Hepatitis E.
2019
It was approved to conduct clinical trials in the United States, becoming the first Chinese vaccine product to conduct clinical trials in the United States.
2020
The Phase I clinical trial was completed in the United States. In the same year, it was approved in Pakistan, contributing Chinese wisdom to the cause of Hepatitis E prevention in that country.
2022
In cooperation with Médecins Sans Frontières (MSF), a Hepatitis E vaccination campaign was carried out in South Sudan, controlling the Hepatitis E epidemic in the region of Bentiu.
2024
The Hepatitis E vaccine was included in the GAVI 2026-2030 investment plan for the first time.
Innovative Vaccine Solutions
Rewriting the History of Viral Vaccine Development
Patent Protection
It has 27 authorized patents at home and abroad, forming a strong intellectual property protection system to ensure technical barriers.
Disruptive Technology
The world's first viral vaccine developed using an Escherichia coli expression system, breaking through traditional perceptions and leading the development of vaccine technology.
Safe and Effective
Its safety, immunogenicity and effectiveness have been proven in clinical trials involving more than 110,000 people, providing a reliable guarantee for Hepatitis E prevention.
Flexible Production
Using an Escherichia coli expression system, the production process is stable and controllable, suitable for large-scale production, and reduces production costs.
International Recognition
Completing the Phase I clinical trial in the United States, it has become a model for Chinese vaccines to go global, demonstrating China's innovation capabilities in biomedicine.
Contribution to Public Health
Filling the gap in the global Hepatitis E vaccine market, it provides a powerful weapon for public health prevention and control in areas affected by Hepatitis E.
For more information : wtexport@ystwt.com
Filing Number:(京)网药械信息备字（2025）第 00190 号
|
Copyright©Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
|
|
京公网安备11011402010353号 
Alibaba Cloud provides cloud computing and security services.|
It supports
|
Powered by CloudDream
|
Terms Of Use|
Privacy Statement